Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor

Bone Marrow Transplantation

Volumn 33, Issue 7, 2004, Pages 697-702

  Kusumi, E ^a   Kami, M ^b   Yuji, K ^a   Hamaki, T ^b   Murashige, N ^b   Hori, A ^b   Kojima, R ^b   Kishi, Y ^b   Kim, S W ^b   Ueyama, J ^a   Miyakoshi, S ^a   Tanosaki, R ^b   Morinaga, S ^a   Mori, S ^b   Heike, Y ^b   Muto, Y ^a   Masuo, S ^c   Taniguchi, S ^a   Takaue, Y ^b  

^a TORANOMON HOSPITAL   (Japan)

^b The National Ca PRer Center Hospital   (Japan)

^c JR Tokyo General Hospital   (Japan)

Author keywords

Antithymocyte globulin; Intermediate dose TBI; Matched unrelated donors; RIST

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PREDNISOLONE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADENOVIRUS; ADULT; ARTICLE; BLADDER DISEASE; BONE MARROW; CARDIOTOXICITY; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DONOR; DRUG DOSE REDUCTION; DRUG FATALITY; ENTEROPATHY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; JAPAN; LIVER TOXICITY; LUNG TOXICITY; MALE; MORTALITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; TIME; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; CLADRIBINE; FEASIBILITY STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 16544368076     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704425     Document Type: Article

References (21)

1. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
2. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
3. Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 2003; 101: 4233-4244.
4. Kodera Y, Morishima Y, Kato S et al. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. Bone Marrow Transplant 1999; 24: 995-1003.
5. Sasazuki T, Juji T, Morishima Y et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339: 1177-1185.
6. Saito T, Kanda Y, Kami M et al. Therapeutic potential of a reduced intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002; 8: 1014-1020.
7. Thiede C, Florek M, Bornhauser M et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055-1060.
8. Kanda Y, Mineishi S, Saito T et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 689-692.
9. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-1332.
10. Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
11. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
12. Wong R, Giralt SA, Martin T et al. Reduced intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment of myeloid malignancies in patients older than 55 years of age. Blood 2003; 102: 3052-3059.
13. Nagler A, Aker M, Or R et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 2001; 29: 362-370.
14. Bornhauser M, Thiede C, Platzbecker U et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001; 7: 2254-2262.
15. Maris MB, Niederwieser D, Sandmaier BM et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021-2030.
16. Eiermann TH, Lambrecht P, Zander AR. Monitoring antithymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 1999; 23: 779-781.
17. Bunn D, Lea CK, Bevan DJ et al. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996; 45: 29-32.
18. Deeg HJ, Amylon ID, Harris RE et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7: 208-215.
19. Takenaka K, Gondo H, Tanimoto K et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19: 241-248.
20. Kanda Y, Mineishi S, Nakai K et al. Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin. Blood 2001; 97: 3676-3677.
21. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-833.